Skip to main content
Erschienen in: World Journal of Urology 4/2014

01.08.2014 | Original Article

Characteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland

verfasst von: F. O’Kelly, S. Elamin, A. Cahill, P. Aherne, J. White, J. Buckley, K. N. O’Regan, A. Brady, D. G. Power, M. F. O’Brien, P. Sweeney, N. Mayer, P. J. Kelly

Erschienen in: World Journal of Urology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The 2005 international society of urological pathology consensus statement on Gleason grading in prostate cancer revised Gleason scoring in clinical practice. The potential for grade migration with this refinement poses difficulties in interpreting historical series. We report the characteristics of a recent cohort of consecutive Gleason score 9 or 10 prostate cancers in our institution. The purpose of this study was to define the clinicopathologic variables and staging information for this high-risk population, and to identify whether traditional prostate staging techniques are adequate for this subcohort of men.

Materials and methods

A computational review of our pathology database was performed. Between May 2010 and September 2012, 1,295 consecutive biopsies were undertaken, 168 of which were high-grade tumours (12.97 %). This group were divided into two cohorts of which 84 (12.05 %) had a highest reported Gleason score of 9 (N = 79) or 10 (N = 5) and 84 were reported as Gleason 8. All biopsies were double-reported by pathologists with a special interest in uropathology.

Results

Men diagnosed with a Gleason pattern 5 tumour were statistically far more likely to have advanced disease on direct rectal examination of the prostate compared with Gleason sum 8 tumours (p < 0.001) and a positive first-degree family history of prostate cancer (p < 0.001). Overall, Gleason sum 9/10 prostate cancers were also found to be statistically more aggressive than Gleason sum 8 tumours on TRUS core biopsy analysis with significantly higher levels of perineural invasion (p < 0.0001) and extracapsular extension (p = 0.001) as well as a higher levels of tumour found within the core biopsy sample. Those men diagnosed with Gleason pattern 5 prostate cancer also had radiological indicators of increased tumour aggressiveness compared with Gleason sum 8 cancer with respect to bone (p = 0.0002) and visceral (p = 0.044) metastases at presentation.

Conclusions

This series of Gleason score 9/10 prostate cancers serves to highlight the large disease burden, adverse pathologic features, and locally advanced nature of this aggressive subtype, which has previously been under-described in the literature, and differs from historical series in having a large high-grade cohort demonstrating high rates of metastatic disease. A history of prostate cancer amongst first-degree relatives was particularly prevalent in this population raising the issue of screening in a high-risk population. The high incidence of visceral metastatic disease at presentation supports upfront staging with CT thorax, abdomen, and pelvis in patients with Gleason 9 or 10 prostate cancers.
Literatur
2.
Zurück zum Zitat Epstein JI (2010) An update of the Gleason grading system. J Urol 183:443 Epstein JI (2010) An update of the Gleason grading system. J Urol 183:443
3.
Zurück zum Zitat Nanda A, Chen MH, Renshaw AA et al (2009) Gleason pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phy 74:1419CrossRef Nanda A, Chen MH, Renshaw AA et al (2009) Gleason pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phy 74:1419CrossRef
4.
Zurück zum Zitat Pierorazio PM, Guzzo TJ, Han M et al (2010) Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology 76:715PubMedCentralPubMedCrossRef Pierorazio PM, Guzzo TJ, Han M et al (2010) Long-term survival after radical prostatectomy for men with high Gleason sum in pathologic specimen. Urology 76:715PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Chan SM, Garcia FJ, Chin JL et al (2011) The clinical significance of in-depth pathological assessment of extraprostatic extension and margin status in radical prostatectomies for prostate cancer. Prostate Cancer Prostatic Dis 14(4):307–312PubMedCrossRef Chan SM, Garcia FJ, Chin JL et al (2011) The clinical significance of in-depth pathological assessment of extraprostatic extension and margin status in radical prostatectomies for prostate cancer. Prostate Cancer Prostatic Dis 14(4):307–312PubMedCrossRef
6.
Zurück zum Zitat Sebo TJ, Bock BJ, Cheville JC et al (2000) The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 163:174–178PubMedCrossRef Sebo TJ, Bock BJ, Cheville JC et al (2000) The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 163:174–178PubMedCrossRef
7.
Zurück zum Zitat D’Amico AV, Whittington R, Malkowicz SB et al (2000) Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18:1164–1172PubMed D’Amico AV, Whittington R, Malkowicz SB et al (2000) Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol 18:1164–1172PubMed
8.
Zurück zum Zitat Freedland SJ, Aronson WJ, Terris MK et al (2003) Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol 169:2136–2141PubMedCrossRef Freedland SJ, Aronson WJ, Terris MK et al (2003) Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database. J Urol 169:2136–2141PubMedCrossRef
9.
Zurück zum Zitat Chaux A, Fajardo DA, Gonzalez-Roibon N et al (2012) High grade prostatic adenocarcinoma present in a single biopsy core is associated with increased extraprostatic extension, seminal vesicle invasion, and positive surgical margins at prostatectomy. Urology 79(4):863–868PubMedCentralPubMedCrossRef Chaux A, Fajardo DA, Gonzalez-Roibon N et al (2012) High grade prostatic adenocarcinoma present in a single biopsy core is associated with increased extraprostatic extension, seminal vesicle invasion, and positive surgical margins at prostatectomy. Urology 79(4):863–868PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Eifler JB, Feng Z, Lin BM et al (2012) An updated prostate cancer staging nomogram (Partin Tables) based on cases from 2006–2011. BJU Int 111:22–29PubMedCrossRef Eifler JB, Feng Z, Lin BM et al (2012) An updated prostate cancer staging nomogram (Partin Tables) based on cases from 2006–2011. BJU Int 111:22–29PubMedCrossRef
11.
Zurück zum Zitat Epstein JI, Allsbrook WC Jr, Amin MB et al (2005) The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242PubMedCrossRef Epstein JI, Allsbrook WC Jr, Amin MB et al (2005) The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol 29:1228–1242PubMedCrossRef
12.
Zurück zum Zitat Uemura H, Hoshino K, Sasaki T et al (2009) Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens. BJU Int 103:1190–1194PubMedCrossRef Uemura H, Hoshino K, Sasaki T et al (2009) Usefulness of the 2005 International Society of Urologic Pathology Gleason grading system in prostate biopsy and radical prostatectomy specimens. BJU Int 103:1190–1194PubMedCrossRef
13.
Zurück zum Zitat Stark JR, Perner S, Stampfer MJ et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459–3464PubMedCentralPubMedCrossRef Stark JR, Perner S, Stampfer MJ et al (2009) Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? J Clin Oncol 27:3459–3464PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Stenmark MH, Blas K, Halverson S et al (2011) Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys 81:e335–e344PubMedCrossRef Stenmark MH, Blas K, Halverson S et al (2011) Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease. Int J Radiat Oncol Biol Phys 81:e335–e344PubMedCrossRef
15.
Zurück zum Zitat Patel AA, Chen MH, Renshaw AA, D’Amico AV (2007) PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 298:1533–1538PubMed Patel AA, Chen MH, Renshaw AA, D’Amico AV (2007) PSA failure following definitive treatment of prostate cancer having biopsy Gleason score 7 with tertiary grade 5. JAMA 298:1533–1538PubMed
16.
Zurück zum Zitat Sabolch A, Feng FY, Daignault-Newton S et al (2011) Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 81:e351–e360PubMedCrossRef Sabolch A, Feng FY, Daignault-Newton S et al (2011) Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation. Int J Radiat Oncol Biol Phys 81:e351–e360PubMedCrossRef
18.
Zurück zum Zitat Epstein JI, Feng Z, Trock BJ et al (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61(5):1019–1024PubMedCrossRef Epstein JI, Feng Z, Trock BJ et al (2012) Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. Eur Urol 61(5):1019–1024PubMedCrossRef
19.
Zurück zum Zitat Moussa AS, Li J, Soriano M et al (2009) Prostate biopsy and clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 103(1):43–48PubMedCrossRef Moussa AS, Li J, Soriano M et al (2009) Prostate biopsy and clinical and pathological variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int 103(1):43–48PubMedCrossRef
20.
Zurück zum Zitat DeLancey JO, Wood DP Jr, He C et al (2013) Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy. Urology 81(2):354–357PubMedCrossRef DeLancey JO, Wood DP Jr, He C et al (2013) Evidence of perineural invasion on prostate biopsy specimen and survival after radical prostatectomy. Urology 81(2):354–357PubMedCrossRef
21.
Zurück zum Zitat Feng FY, Qian Y, Stenmark MH et al (2011) Perineural invasion predicts increased recurrence, metastasis and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys 81(4):e361–e367PubMedCrossRef Feng FY, Qian Y, Stenmark MH et al (2011) Perineural invasion predicts increased recurrence, metastasis and death from prostate cancer following treatment with dose-escalated radiation therapy. Int J Radiat Oncol Biol Phys 81(4):e361–e367PubMedCrossRef
22.
Zurück zum Zitat Nanda A, Chen MH, Renshaw AA et al (2009) Gleason pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 74(5):1419–1423PubMedCrossRef Nanda A, Chen MH, Renshaw AA et al (2009) Gleason pattern 5 prostate cancer: further stratification of patients with high-risk disease and implications for future randomized trials. Int J Radiat Oncol Biol Phys 74(5):1419–1423PubMedCrossRef
23.
Zurück zum Zitat Moreira DM, Banez LL, Presti JC et al (2010) Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the shared equal access regional cancer hospital database. BJU Int 105(1):28–33PubMedCrossRef Moreira DM, Banez LL, Presti JC et al (2010) Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the shared equal access regional cancer hospital database. BJU Int 105(1):28–33PubMedCrossRef
24.
Zurück zum Zitat Elshafei A, Moussa AS, Hatem A et al (2013) Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy. Urology 81(4):826–830PubMedCrossRef Elshafei A, Moussa AS, Hatem A et al (2013) Does positive family history of prostate cancer increase the risk of prostate cancer on initial prostate biopsy. Urology 81(4):826–830PubMedCrossRef
25.
Zurück zum Zitat Roudgari H, Hemminki K, Brandt A et al (2012) Prostate cancer risk assessment model: a scoring model based on the Swedish family-cancer database. J Med Genet 49(5):345–352PubMedCrossRef Roudgari H, Hemminki K, Brandt A et al (2012) Prostate cancer risk assessment model: a scoring model based on the Swedish family-cancer database. J Med Genet 49(5):345–352PubMedCrossRef
26.
Zurück zum Zitat Jansson KF, Akre O, Garmo H et al (2012) Concordance of tumour differentiation among brothers with prostate cancer. Eur Urol 62(4):656–661PubMedCrossRef Jansson KF, Akre O, Garmo H et al (2012) Concordance of tumour differentiation among brothers with prostate cancer. Eur Urol 62(4):656–661PubMedCrossRef
28.
Zurück zum Zitat Holmstrom B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Stattin P, National Prostate Cancer Registry of Sweden (2010) Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol 184:1322–1327PubMedCrossRef Holmstrom B, Holmberg E, Egevad L, Adolfsson J, Johansson JE, Stattin P, National Prostate Cancer Registry of Sweden (2010) Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol 184:1322–1327PubMedCrossRef
29.
Zurück zum Zitat O’Brien D, Loeb S, Carvalhal GF et al (2011) Delay of surgery in men with low risk prostate cancer. J Urol 185:2143–2147PubMedCrossRef O’Brien D, Loeb S, Carvalhal GF et al (2011) Delay of surgery in men with low risk prostate cancer. J Urol 185:2143–2147PubMedCrossRef
30.
Zurück zum Zitat Lee N, Newhouse JH, Olsson CA et al (1999) Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 54(3):490–494PubMedCrossRef Lee N, Newhouse JH, Olsson CA et al (1999) Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 54(3):490–494PubMedCrossRef
31.
Zurück zum Zitat Masterson TA, Touijer K (2008) The role of endorectal coil MRI in preoperative staging and decision-making for the treatment of clinically localized prostate cancer. MAGMA 21(6):371–377PubMedCrossRef Masterson TA, Touijer K (2008) The role of endorectal coil MRI in preoperative staging and decision-making for the treatment of clinically localized prostate cancer. MAGMA 21(6):371–377PubMedCrossRef
Metadaten
Titel
Characteristics of modern Gleason 9/10 prostate adenocarcinoma: a single tertiary centre experience within the Republic of Ireland
verfasst von
F. O’Kelly
S. Elamin
A. Cahill
P. Aherne
J. White
J. Buckley
K. N. O’Regan
A. Brady
D. G. Power
M. F. O’Brien
P. Sweeney
N. Mayer
P. J. Kelly
Publikationsdatum
01.08.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
World Journal of Urology / Ausgabe 4/2014
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-013-1184-2

Weitere Artikel der Ausgabe 4/2014

World Journal of Urology 4/2014 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

S3-Leitlinie zur unkomplizierten Zystitis: Auf Antibiotika verzichten?

15.05.2024 Harnwegsinfektionen Nachrichten

Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

12.05.2024 Prostatakarzinom Nachrichten

Ein hoher Anteil pflanzlicher Nahrung trägt möglicherweise dazu bei, das Progressionsrisiko von Männern mit Prostatakarzinomen zu senken. In einer US-Studie war das Risiko bei ausgeprägter pflanzlicher Ernährung in etwa halbiert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.